Efficacy and safety of anti-Trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: JOURNAL OF CLINICAL ONCOLOLOGY Year:2017 | Volume:35 | Issue:19 Page(s): 2141-2148

Download Full-Text

View:

Download:

Cites:

Information Journal Paper

Title

Efficacy and safety of anti-Trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer

Author(s)

| Issue Writer Certificate

Keywords

Not Registered.

Abstract

Cites

Antibody-Drug Conjugates: Possibilities and Challenges (Review Article)

References

No record.

Cite

APA: Copy

. (2017). Efficacy and safety of anti-Trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. JOURNAL OF CLINICAL ONCOLOLOGY, 35(19), 2141-2148. SID. https://sid.ir/paper/749876/en

Vancouver: Copy

. Efficacy and safety of anti-Trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. JOURNAL OF CLINICAL ONCOLOLOGY[Internet]. 2017;35(19):2141-2148. Available from: https://sid.ir/paper/749876/en

IEEE: Copy

, “Efficacy and safety of anti-Trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer,” JOURNAL OF CLINICAL ONCOLOLOGY, vol. 35, no. 19, pp. 2141–2148, 2017, [Online]. Available: https://sid.ir/paper/749876/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops